On October 6, AIM Vaccine completed its global offering and listing on The Stock Exchange of Hong Kong Limited, raising gross proceeds of approximately US$20 million. AIM Vaccine’s market capitalization at listing is approximately US$2.49 billion.
AIM Vaccine is the second largest vaccine company and the largest among all privately-owned vaccine companies in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines). It is also the only China-based vaccine company that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies.
S&C acted as Hong Kong and U.S. counsel to AIM Vaccine.
The S&C team was led by Kay Ian Ng and Ching-Yang Lin in Hong Kong and Gwen Wong in Beijing. Jeffrey Hochberg and Saul Brander in New York and Michael Orchowski in London advised on U.S. tax matters.